2006
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia
Krystal JH, D’Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10: 235-252. PMID: 17197373, DOI: 10.1007/bf03033360.Peer-Reviewed Original ResearchConceptsSubstance abuse riskSubstance abuseSubstance abuse disordersAbuse riskSubstances of abuseNicotinic cholinergicPatient groupDopaminergic inputAbused substancesAbuse disordersSchizophrenic patientsDysphoric effectsAbuse liabilityHigh dosesLow dosesNegative symptomsReceptor functionAltered responseSchizophreniaSchizophrenic individualsRiskReward processingSubjective distressImpulsive behaviorDoses
1999
Assessment of the Safety and Efficacy Data for the Hypnotic Halcion(R): Results of an Analysis by an Institute of Medicine Committee
Gibbons R, Brown B, Azarnoff D, Bunney W, Cancro R, Gillin J, Hullett S, Killam K, Krystal J, Kupfer D, Stolley P, Pope A, French G. Assessment of the Safety and Efficacy Data for the Hypnotic Halcion(R): Results of an Analysis by an Institute of Medicine Committee. Journal Of The American Statistical Association 1999, 94: 993-1002. DOI: 10.1080/01621459.1999.10473852.Peer-Reviewed Original ResearchInstitute of MedicineEfficacy dataCurrent product labelingDuration of treatmentTreatment of insomniaPossible side effectsHypnotic effectivenessChronic insomniaSide effectsLow dosesAdult populationIOM reportMedicine CommitteeLabeling changesDifferent dosesU.S. FoodTask Force ReportDutch psychiatristsInsomniaProduct labelingDosesHalcionForce ReportPossible linkSafety